orphan drug designation
orphan drug designation
SynaptixBio Receives FDA ODD for Leukodystrophy Treatment
BIOT
📰 Rare disease specialist SynaptixBio Ltd receives FDA ODD for TUBB4A leukodystrophy, allowing research on therapy for isolated hypomyelination. 💊💡✨
